Navigation Links
VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement

ROCHESTER, N.Y., Jan. 28, 2011 /PRNewswire/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, today announced that before the market opens on Thursday, February 24, 2011 it will release its fourth quarter and full year 2010 financial results. The company will host a conference call that morning at 11:00 a.m. EST.

VirtualScopics' President and Chief Executive Officer, Jeff Markin, and Chief Business and Financial Officer, Molly Henderson, will provide a business update and discuss the company's results for the quarter and year ended December 31, 2010 during the conference call.

Interested participants should call 877-407-8035 when calling within the United States or 201-689-8035 when calling internationally.  This call can also be accessed at and will be available for 30 days after the call.

About VirtualScopics, Inc.VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit

Forward-Looking Statements The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACTS:Investor Relations:Company Contact:Tim Ryan

Molly HendersonThe Shoreham Group

Chief Business and Financial Officer, Sr. Vice President80 Eighth Ave, Ste 1107

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242 7777 Direct

+1 585

SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Reports 3rd Quarter 2010 Results; Revenues Increase 28%
2. VirtualScopics Schedules Third Quarter 2010 Earnings Announcement
3. VirtualScopics Revenues Hit Another Quarterly Record
4. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
5. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
6. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
7. VirtualScopics Added to Russell Microcap Index
8. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
9. VirtualScopics Receives Issuance in Japan of Prominent Patent
10. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
11. VirtualScopics to Present at the 8th Annual Bio Investor Forum
Post Your Comments:
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):